Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment
A Prospective and Open-Label Study of the Effect on Proximal Tubular Function in Asian-American Patients Receiving Tenofovir Disoproxil Fumarate (TDF) or Entecavir (ETV) for HBV Treatment
Sponsor: New Discovery LLC
Terminated
This trial was terminated. No reason was provided.
Listed as NCT01715987, this observational or N/A phase trial focuses on Hepatitis B and remains terminated or withdrawn. Sponsored by New Discovery LLC, it has been updated 11 times since 2012, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 6 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Terminated NA
-
Aug 2017 — Oct 2017 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- New Discovery LLC
For direct contact, visit the study record on ClinicalTrials.gov .